Top-level Industry leaders from around 25+ Countries come to join CTIP and leave with an exceptional experience that they return to the conferences year after year. Delegates attending our event are asked to complete a questionnaire, which confirms their clinical R&D budget. They also provide details on:
BDD is a specialist drug formulation company providing expertise across all areas of drug delivery. We offer a full-service package to fit individual needs from troubleshooting, formulation development, in vitro and in vivo testing and full technology transfer.
Their patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Their clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report.
They specialize in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behavior of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.
Clinerion accelerates clinical research and medical access to treatments for patients. They use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.
Their technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. They create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Metronomia Clinical Research GmbH is a mid-size European CRO, providing full- or tailored services in clinical trials phase I – IV and NIS, with a special focus on biostatistics, data management and e-clinical services. Metronomia's mission statement is to improve and accelerate drug development by bringing together user friendly e-clinical technologies, well accepted study designs and pronounced customer orientation. Since more than 20 years our customers particularly esteem the high-quality and reliability of their data, our commitment to best service and outstanding flexibility, our stable project teams and the competitive cost-benefit ratio. Metronomia has a proven track record in all major therapeutic areas (core indications being oncology, dermatology, transplantation, nephrology and pulmonary diseases).
Ramus Medical is a full service CRO located in Sofia, Bulgaria. The company is providing services from Protocol to Final Report through RA consultancy, Clinical Monitoring, Site Management, GxP Auditing, Bioanalysis (HPLC and LC-MS/MS), Statistics and Data Management, covering clinical trials in Phase I to Phase IV. Since 2010 Ramus Medical have successfully completed more than 30 clinical trials Phase I – IV, including BE/BA studies. Their mission is to provide reliable services to our partners and together to achieve the common goal of improved health. Since 2018 Ramus has its own Phase I unit and Medical Cetre.
MZD GmbH was founded in 1994 and is one of the leading recruitment agencies in clinical research. They place specialists from the field of clinical research – both freelancers and permanent employees – in the pharmaceutical, medical device and biotechnology industries. Their services range from consultancy regarding the entire spectrum of insourcing and outsourcing management to selecting the best possible candidates for phase I to IV of clinical research from any kind of indicator group. Today, a constantly growing global network of more than 3,100 specialists for clinical research draws upon the excellent services provided by MZD. So their customers can focus entirely on their fields of expertise.
Founded in 2015, INNOPLEXUS AG is headquartered in Eschborn, Germany with offices in Pune, India, and Hoboken & San Francisco, USA.
At INNOPLEXUS they are helping organisations move to continuous decision-making by generating broader, deeper and faster insights from structured and unstructured private and public data leveraging cutting-edge, patent-pending Artificial Intelligence, Blockchain, and advanced analytics technologies.
They aim to transform batch decision making in enterprises into an empowered, inspired and faster continuum. They focus on industries that need to constantly evaluate and improve their efficiency, reduce cost and mitigate risk to keep up with the changing business environment - like global banking, life sciences, and pharmaceutical companies.
In addition to strengthening research efforts, they work to help healthcare organizations leverage technologies to expedite drug development process across all stages - preclinical, clinical, regulatory and commercial. Whether a drug developer is seeking existing research, a medical researcher is searching for alternative treatments, or a practitioner is attempting to find data on a particular disease - increasing access to relevant information removes roadblocks to discovery and fuels rapid growth.
VALOS’ experienced statisticians and skilled SAS® Statistical programmers can deliver better quality and on-time completion of projects, helping you to drive your clinical trial’s success.
Their team is made of clinical research professionals, having strong education, wide experience and on-going training of the main industry information (such as 21 CFR Part 11 or GCP), market trends and industry standards such as Clinical Data Interchange Standards Consortium (CDISC)
Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 8 own operational offices in Bulgaria, Czech Republic, Hungary, India, Kazakhstan, Moldova, Poland, Romania, Russia, Slovakia, Ukraine, USA and is a founding partner of a network of reliable partners in Scandinavia and Western Europe. GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Their monitors and project managers are all certified clinicians experienced in GCP clinical research. Their experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines. GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients. Meanwhile, in the recent years the number of our clients worldwide increased dramatically. They actively participate in specialized industry events worldwide.
Bay Area Research Logistics (BARL) is known for its superior management of clinical trial services – from drug procurement to blinding, packaging, labeling, storing and distribution. They provide seamless coordination for all sizes of trials - from large, global phase IV trials to small-scale INDs, across many therapeutic classifications ranging from Phase I to Phase IV studies.
BARL is the preferred vendor to manage the vaccine and biological trials for the Canadian clinical supplies’ operations to some of the world’s largest pharmaceutical and academic institutions, as well as for a number of innovative biotech companies in North America.
Our services include, but are not limited to:
• Planning - We will help you to develop plans to ensure studies are run efficiently. Plans are based on the specific needs of your clinical trial such as, investigational product designs, regulatory requirements, funding, and sourcing or procurement of comparator products and ancillary supplies
• Packaging - BARL can accommodate complex temperature requirements for packaging and labeling in order to meet product needs while ensuring flexibility to overcome obstacles without compromising timelines
• Labeling - We can provide label design and printing compliant with customer requirements and GMP/GCP guidelines
• Storage - Our cGMP, BSL2 licensed, and dangerous goods certified environment is a 24/7 electronically alarmed and monitored facility with the ability to accommodate all storage requirements from ultra-frozen to ambient temperatures
• Distribution - We ensure quick and compliant delivery using the most efficient and effective couriers with multiple solutions available for temperature control depending on your specific product requirements
• Special Access Program Services - Capacity to store and distribute SAP products at our cGMP compliant facility with 24/7 coverage to ensure on-demand patient needs are met
Sai Life Sciences is built on the bedrock of partnership. They work with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules for a healthier tomorrow. Their Vision is to support global innovator partners bring 25 new medicines to life by 2025. And they are well on that journey.
Exom Group is “The Human Digital CRO”, that provides value-added services through digital applications for clinical development of drugs & medical devices. Exom combines the strong medical, regulatory and operational expertise of his staff, with the most disruptive digital cloud and mobile solutions to reduce costs and increase quality and performance of clinical trials. Exom will be the Preferred Partner for those life science companies who recognize that implementing digital solutions is not as simple as installing innovative technologies but really a fundamental change in the way they do clinical trials with a higher attention to both investigators and patient’s needs. Exom helps in containing the costs, reducing the time to market, facing the regulatory pressures and managing the complexity and the level of the burden in clinical operations. Exom Alliance, a network of validated partners, provides a qualified, flexible and established organization of experienced clinical research professionals active across the whole of Europe and USA, all trained and familiar with Exom’s technologies and processes.
Mondosano is a patient-centric digital recruitment provider based in Hamburg Germany. They help pharma companies as well as CROs to recruit suitable patients for ongoing trials and market research projects with the help of our database of registered patients and online recruitment campaigns. Mondosano is specialized in data-driven patient recruitment, as well as patient engagement and patients insight campaigns.
Biocair is a global specialist courier with over 30 years of dedicated experience in the
pharmaceutical, biotechnology and life science sectors. Specifically, we provide dedicated,
specialised logistics services – both the systems and the people – for the scientific sector and
our services are the most comprehensive of its kind available on the market.
The company has built up a unique, client-centric approach by employing scientists in frontline logistics positions and assembling a team of best-in-class industry experts in quality, cold
chain and regulatory compliance amongst others. Biocair focuses on providing the most
comprehensive time-sensitive and temperature-controlled logistics services available whilst
delivering flexible, tailored, cost effective solutions to all clients.
The Biocair network spans more than 850 locations in over 160 countries across Europe,
Africa, Asia and the Americas.
“I would Definitely recommend this event; it is very informational and I very much enjoyed my visit here.”
Acc Manager Ara Research
“I’ve already communicated to my collogues about the upcoming CTIP & we're already planning to attend based on this experience so far, I will recommend you give it a try, if you have never been to one of their conferences.”
Sr. Director, eClinical Solutions Intrinsic Clinical Systems
“I would Definitely recommend this event. It is very informational and I very much enjoyed my visit here.”
Strategikon Pharma is an expert-led, innovation-driven, agile, emerging new leader in the clinical trial business management space. We are a Woman-Owned Small Business, and cloud-based technology platform company funded by Silicon Valley and made up of industry veterans with experience on both the Sponsor and CRO side. Clinical Maestro is our flagship product; it is a fully digital system for clinical trial planning, budgeting, sourcing, vendor management and financial performance metrics management.
Our Clinical Maestro solution is absolutely unique in the industry – there are just no substitute products out there with the same breadth of novel solutions and collaborative infrastructure that have the potential to transform the industry. This is largely because we are not trying to build a product to sell to pharma companies or CROs, rather we are trying to solve an age-old problem that has plagued the industry with inefficiency since the introduction of computers and email. Our vision incorporates moving away from traditional Excel-driven manual methods of budgeting, sourcing and vendor management and metrics and into the age of workflow automation and artificial intelligence. Clinical Maestro brings order to the RFP process by assembling and organizing inputs from all stakeholders to create a shared digital standard. A good visualization of the current state of the industry is that each Sponsor and each CRO is playing their own musical instrument, their own song, in their own style, alone, in a corner. Clinical Maestro brings all these players together in unison to create a beautiful symphony. Together, with the right technology and tools, we believe we can get there.
We have seen amazing innovation start to flourish in the business processes around clinical development. I call it the Administrative Revolution of clinical trials. These include simplified, digitized and automated solutions for vendor discovery and payment, site and patient compensation, and whole process evolution for planning, sourcing, financial performance metrics and engaging with vendors such as Clinical Maestro’s digital Transaction Room and Governance dashboards. Furthermore, artificial intelligence has a mega role to play in our ability to use predictive analytics to better mine one’s own data sets and collective, anonymized data sets such as Clinical Maestro’s Intelligence Bank and Data Trove. Other areas that will change the game include using AI for at-home dosing, patient access and patient engagement. I am personally very excited by the use of video communication technology and localized contract staffing models to reach patients in remote areas. Lots of exciting things are happening that should propel our ability to deliver life-saving and life-improving therapies to patients in need.
Early adoption; with any new technology solution there tends to be a hockey-stick pattern of adoption – no one wants to be first and no one wants to be last. Having been founded in 2016, Strategikon Pharma is still a young company in a very conservative, slow-moving, and highly regulated industry. Our solution is so novel, so mind-blowing in its ability to disrupt current highly manual processes and deliver efficiencies that we are finding clients need time to digest the potential impacts. These include politicized corporate challenges such as replacing old, underutilized, embedded legacy applications, and even threatening existing low-productivity empires. We are addressing major industry pain points and are confident that our product is the absolute best on the market. Therefore, we are highly focused on Advocacy and Thought-Leadership to help educate the market, engaging the most open-minded and technology-savvy movers and shakers in the industry to champion our system, and of course building ongoing strong investor backing to help us weather the long sales cycles. In short - we aren’t going anywhere and are committed to bringing the future forward!
1. Inertia – there are many numerous new technologies available on the market that could really help solve industry problems but most are being brought forth by small, innovative companies that need to survive in order to move the dial. Many larger drug companies are taking a passive approach and expecting vendors to solve their internal issues with very broad, customized solutions that will require M&A activity. I worry that by waiting for these small players to consolidate into larger-scale providers, the industry to lose some of the innovation edge and nimble service benefits that small organizations can deliver today. 2. Conservatism – similarly, as much as we like to think of the pharmaceutical industry as being “high-tech”, we really haven’t changed that much in the past 40 years or even 20 years. In fact, much of the advances in communication have created more busywork and distractions. Each of us industry professionals need to look within at how our own daily behaviors and working practices could be improved to drive greater productivity and impact. We believe without a return of focus to analysis, strategy, action, performance and change, drug development will continue to elongate which drives up cost and risk. We owe it to patients to innovate and evolve. 3. Balance of Power – in my prior role at a Top CRO, I experienced the integration of commercial services into clinical solution strategies. This was a mega eye opener for me to start to appreciate this completely other world, and I will never forget the words of our CEO who led the assembly of this model back in 2011. He talked about the future being one in which drug companies are paid not for supplying drugs, but for achieving Health Outcomes. This, along with the introduction of greater efforts to hear the voice of the patient and the growth of formal patient advocacy groups, will finally start to change the dynamic towards one where the real customers of our industry achieve a greater balance of power. I believe this connection to the communities we serve and the accomplishments we deliver is essential for our industry to remain relevant and thrive.
It is important for us to attend CTIP because we have an excellent message to share and are eager to seek out other like-minded professionals who are thirsty for innovation. We hope that CTIP will help us expand minds while making new friends and partners in the process.
I have been working in the industry for 16 years, in various roles and capacities, and have been strongly rooted in the data world for clinical research. Over the years, while expanding my own knowledge and scope into clinical development operations, my latest roles have brought me to be highly engaged with customers and colleagues from a development perspective in getting small to medium size biotech/device companies to the clinical development stage and their programs moving.
I believe that what we are offering at Crown CRO, though a Full-Service CRO with truly in-house services, we differ in the way we interact with our customers. Knowing that time is precious and focusing on the aspects that are important for our customers and their programs, we have strived to offer subject matter experts even at early discussion stages to utilize everyone’s time in an optimal way. Getting right to the heart of the challenges and needs of our customers has proven to be more advantageous in getting programs to advance rather than overwhelming decision makers with irrelevant “pitches”.
Establishing trusted collaborator groups and integrator roles, that not only can provide core services from their own in-house portfolios but also those with wide networks of experts with aligned expectations and understanding of not only the program but the objectives – scientific and business.
We have made great investments into our service offerings in order to truly have in-house (not subcontracted) services as well as establishing our Commercial Innovations & Office to initiate discussions with customers and potential customers to provide subject matter expertise from the start.
Our Early Development consulting and Integrator services have increased starkly over the past year proving that our collaborative positioning and deep dedication to our customers is key from day 1.
After the establishment and investment into our own Data Services and Pharmacovigilance – we are taking steps toward further technological innovations and partnerships. We have a well-established partnership with IBM Watson Health as an example of these first steps to advance quickly in terms of technology and advanced approaches to Clinical Research.
My expectation is to be able to not only have meaningful discussions with industry peers and share experience, but also to highlight Crown CROs strength and capabilities not only in our region but in global clinical development.
Though we have a wide range of customers (from large pharma to virtual biotech), one of our strong focuses is in helping industry new comers as well existing small and virtual biotech see their programs through to clinical and support during the clinical phases in a transparent, flexible and reliable manner.
Embassy Suites by Hilton Boston at Logan Airport | Boston , MA
207 Porter Street, Boston, Massachusetts, 02128, USA